Abstract:Background: DNA methylation is involved in numerous biologic events and associates with transcriptional gene silencing, playing an important role in the pathogenesis of endometrial cancer. ESR1/PGR frequently undergoes de novo methylation and loss expression in a wide variety of tumors, including breast, colon, lung, and brain tumors. However, the mechanisms underlying estrogen and progesterone receptors (ER/PR) loss in endometrial cancer have not been studied extensively. The aims of this study were to determine the expression of DNA (cytosine-5)-methyltransferase 3A/3B (DNMT3A/3B) in endometrial cancer to investigate whether the methylation catalyzed by DNMT3A/3B contributes to low ER/PR expression. Methods: The clinicopathologic information and RNA-Seq expression data of DNMT3A/3B of 544 endometrial cancers were derived from The Cancer Genome Atlas (TCGA) uterine cancer cohort in May 2018. RNA-Seq level of DNMT3A/3B was compared between these clinicopathologic factors with t-test or one-way analysis of variance. Results: DNMT3A/3B was overexpressed in endometrioid carcinoma (EEC) and was even higher in non-endometrioid carcinoma (NEEC) (DNMT3A, EEC vs. NEEC: 37.6% vs. 69.9%, t= -7.440, P < 0.001; DNMT3B, EEC vs. NEEC: 42.4% vs. 72.8%, t= -6.897, P < 0.001). In EEC, DNMT3A overexpression was significantly correlated with the hypermethylation and low expression of the ESR1 and PGR (P <0.05). The same trend was observed in the DNMT3B overexpression subgroup. In the ESR1/ PGR low-expression subgroups, as much as 83.1% of ESR1 and 59.5% of PGR were hypermethylated, which was significantly greater than the ESR1/PG R high-expression subgroups (31.3% and 11.9%, respectively). However. the above phenomena were absent in NEEC, while DNMT3A13B overexpression, ESR1/PGR hypermethylation, and low ER/PR expression occurred much more often. In univariate analysis, DNMT3A/3B overexpressions were significantly correlated with worse prognosis. In multivariate analysis, only DNMT3A was an independent predictor of disease-free survival (P < 0.05). Conclusions: DNMT3A13B expression increases progressively from EEC to NEEC and is correlated with poor survival. The mechanisms underlying low ER/PR expression might be distinct in EEC vs. NEEC. In EEC, methylation related to DNMT3A/3B overexpression might play a major role in ER/PR downregulation.

Promoter Methylation of the <i>MGRN1</i> Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients

Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer

Promoter Methylation Changes in DNA Damage-Response Genes in Ovarian Cancer and Their Correlation with Prognosis

Deletion of OPCML Gene and Promoter Methylation in Ovarian Epithelial Carcinoma

A Polygenic Methylation Prediction Model Associated with Response to Chemotherapy in Epithelial Ovarian Cancer.

Prognostic Significance of Aberrant Gene Methylation in Gastric Cancer.

Expression and Promoter Methylation Status of Mismatch Repair Gene Hmlh1 and Hmsh2 in Epithelial Ovarian Cancer.

DNMT3A/3B Overexpression Might Be Correlated with Poor Patient Survival, Hypermethylation and Low Expression of ESR1/PGR in Endometrioid Carcinoma: an Analysis of the Cancer Genome Atlas

Clinicopathological Significance and Prognostic Value of Dna Methyltransferase 1, 3a, and 3b Expressions in Sporadic Epithelial Ovarian Cancer

High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer

Hypomethylated Gene NRP1 is Co-Expressed with PDGFRB and Associated with Poor Overall Survival in Gastric Cancer Patients.

LncRNA LINC00261 associates with chemoresistance and clinical prognosis in patients with epithelial ovarian cancer

Multidrug Resistance Affects the Prognosis of Primary Epithelial Ovarian Cancer.

Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer.

[Methylation status of RASSF1A and clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer].

Brca1 Promoter Hypermethylation in Sporadic Epithelial Ovarian Carcinoma: Association with Low Expression of Brca1, Improved Survival and Co-Expression of Dna Methyltransferases

LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer

Exploration Of The Role Of M(6) A Rna Methylation Regulators In Malignant Progression And Clinical Prognosis Of Ovarian Cancer

Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Ovarian Cancer